GENERATION BIO CO (GBIO) Stock Fundamental Analysis
NASDAQ:GBIO - Nasdaq - US37148K1007 - Common Stock - Currency: USD
GBIO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. While GBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. GBIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
GBIO had negative earnings in the past year.
In the past year GBIO has reported a negative cash flow from operations.
GBIO had negative earnings in each of the past 5 years.
In the past 5 years GBIO always reported negative operating cash flow.
1.2 Ratios
GBIO has a better Return On Assets (-35.72%) than 60.36% of its industry peers.
GBIO has a Return On Equity (-98.09%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.72% | ||
| ROE | -98.09% | ||
| ROIC | N/A |
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
GBIO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GBIO has been increased compared to 5 years ago.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -5.09, we must say that GBIO is in the distress zone and has some risk of bankruptcy.
GBIO has a Altman-Z score of -5.09. This is in the lower half of the industry: GBIO underperforms 60.36% of its industry peers.
There is no outstanding debt for GBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.09 |
ROIC/WACCN/A
WACC9.77%
2.3 Liquidity
GBIO has a Current Ratio of 8.43. This indicates that GBIO is financially healthy and has no problem in meeting its short term obligations.
GBIO has a better Current ratio (8.43) than 72.73% of its industry peers.
A Quick Ratio of 8.43 indicates that GBIO has no problem at all paying its short term obligations.
GBIO has a better Quick ratio (8.43) than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.43 | ||
| Quick Ratio | 8.43 |
3. Growth
3.1 Past
GBIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -132.94%.
Looking at the last year, GBIO shows a very strong growth in Revenue. The Revenue has grown by 146.37%.
EPS 1Y (TTM)-132.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.43%
Revenue 1Y (TTM)146.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.91%
3.2 Future
The Earnings Per Share is expected to grow by 13.18% on average over the next years. This is quite good.
The Revenue is expected to grow by 12.39% on average over the next years. This is quite good.
EPS Next Y76.95%
EPS Next 2Y32.98%
EPS Next 3Y22.08%
EPS Next 5Y13.18%
Revenue Next Year-17.47%
Revenue Next 2Y-52.86%
Revenue Next 3Y-15.61%
Revenue Next 5Y12.39%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as GBIO's earnings are expected to grow with 22.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.98%
EPS Next 3Y22.08%
5. Dividend
5.1 Amount
No dividends for GBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.04
-0.06 (-1.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.78%
Inst Owner Change-2.1%
Ins Owners2.87%
Ins Owner Change0.09%
Market Cap27.07M
Analysts81.67
Price Target71.4 (1667.33%)
Short Float %N/A
Short Ratio0.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.18%
Min EPS beat(2)-4.08%
Max EPS beat(2)26.43%
EPS beat(4)2
Avg EPS beat(4)8.35%
Min EPS beat(4)-9.16%
Max EPS beat(4)26.43%
EPS beat(8)4
Avg EPS beat(8)-15.96%
EPS beat(12)6
Avg EPS beat(12)-9.5%
EPS beat(16)8
Avg EPS beat(16)-8.43%
Revenue beat(2)2
Avg Revenue beat(2)182.83%
Min Revenue beat(2)64.24%
Max Revenue beat(2)301.43%
Revenue beat(4)4
Avg Revenue beat(4)190.94%
Min Revenue beat(4)64.24%
Max Revenue beat(4)301.43%
Revenue beat(8)7
Avg Revenue beat(8)139.49%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)976.92%
PT rev (3m)937.04%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-923.96%
EPS NY rev (1m)0%
EPS NY rev (3m)3.27%
Revenue NQ rev (1m)23.04%
Revenue NQ rev (3m)45.51%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)121.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.37 | ||
| P/tB | 0.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.94
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-12.83
FCFYN/A
OCF(TTM)-12.72
OCFYN/A
SpS3.67
BVpS10.95
TBVpS10.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -35.72% | ||
| ROE | -98.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.35%
ROA(5y)-35.88%
ROE(3y)-87.81%
ROE(5y)-64.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.33% | ||
| Cap/Sales | 2.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.43 | ||
| Quick Ratio | 8.43 | ||
| Altman-Z | -5.09 |
F-Score5
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)120.26%
Cap/Depr(5y)130.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-132.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.43%
EPS Next Y76.95%
EPS Next 2Y32.98%
EPS Next 3Y22.08%
EPS Next 5Y13.18%
Revenue 1Y (TTM)146.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.91%
Revenue Next Year-17.47%
Revenue Next 2Y-52.86%
Revenue Next 3Y-15.61%
Revenue Next 5Y12.39%
EBIT growth 1Y40.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.99%
OCF growth 3YN/A
OCF growth 5YN/A